Last updated: February 28, 2026
What is NDC 72205-0086?
NDC 72205-0086 is a biosimilar product marketed in the United States. It is a biosimilar version of a biologic reference product, which typically targets specific therapeutic areas such as autoimmune diseases, cancers, or other chronic conditions. For purposes of this analysis, it is assumed to be a biosimilar of infliximab, given the NDC coding pattern, but exact identity should be confirmed from product labels.
Market Overview
Therapeutic Area: The primary market involves autoimmune diseases, including rheumatoid arthritis, Crohn’s disease, ulcerative colitis, and ankylosing spondylitis. The biologic reference, infliximab (Remicade), generated approximately $6 billion in U.S. sales in 2022.
Market Penetration: Biosimilars of infliximab entered the U.S. market in 2016. Market acceptance has grown, but some barriers include physician prescribing habits and formulary preferences. By 2022, biosimilars captured roughly 40% of infliximab prescriptions.
Competitive Landscape: Major biosimilars like Inflectra, Renflexis, and Avsola also compete within this space. Pricing strategies aim to undercut reference biologics by 10-30%.
Revenue and Market Size Estimates
| Year |
Total infliximab sales (USD billion) |
Biosimilar share |
Estimated biosimilar sales (USD billion) |
| 2022 |
6.0 |
40% |
2.4 |
| 2023 |
6.2 |
45% |
2.79 |
| 2024 |
6.3 |
50% |
3.15 |
| 2025 |
6.4 |
55% |
3.52 |
Assumptions: Incremental growth reflects increased biosimilar uptake, driven by pricing, formulary wins, and institutional preferences.
Price Projections
Current Pricing (2023): Wholesale acquisition cost (WAC) for biosimilars of infliximab averages around $700–$900 per vial (varies by manufacturer). These are approximately 20-30% lower than reference biologic prices (~$1,150/vial).
Future Trends (2024–2028):
- Price Decrease: Biosimilar prices are likely to decrease further as market becomes more competitive, with discounts rising to 35–50% against biologic reference.
- Average Selling Price (ASP): Projected to fall to $600–$700 per vial by 2028.
- Market share: Expected to reach 60%–70% of infliximab prescriptions, increasing volume and total sales.
| Year |
Average BPA per vial |
Expected market share |
Revenue (USD billion) |
| 2024 |
$750 |
50% |
3.15 |
| 2025 |
$700 |
55% |
3.52 |
| 2026 |
$680 |
60% |
3.93 |
| 2028 |
$620 |
70% |
4.86 |
Note: Price reductions may be mitigated by manufacturing costs, regulatory changes, and payer negotiations, but downward pressure is predominant.
Pricing Impacts and Market Dynamics
- Pricing Strategy: Manufacturers primarily compete on price, aiming to undercut reference biologics significantly while maintaining profitability.
- Reimbursement: CMS and private payers favor biosimilars, pushing for formularies that favor lower-cost alternatives.
- Manufacturing costs: Estimated to be around $100–$200 per vial, leaving significant margin potential even at reduced prices.
Risks and Variables
- Regulatory delays or modifications could impede biosimilar approvals or launch timelines.
- Patent litigation may prolong exclusivity of reference biologics, delaying biosimilar market penetration.
- Physician and patient acceptance remains critical; skepticism toward biosimilars can slow adoption.
- Biologic price inflation in reference products could influence biosimilar pricing strategies and market dynamics.
Key Takeaways
- The biosimilar represented by NDC 72205-0086 has significant growth potential within the autoimmune disease treatment market.
- It is expected to capture substantial market share, reaching up to 70% of infliximab prescriptions by 2028.
- Average prices are projected to decline to $620–$700 per vial, driven by increasing competition and payer policies.
- The overall biosimilar market could generate USD 4.86 billion annually by 2028, based on volume increases and price declines.
- Market entry risks include patent litigation, regulatory delays, and physician skepticism, which could alter projections.
FAQs
Q1: What is the primary therapeutic use for this biosimilar?
A1: It likely targets autoimmune diseases such as rheumatoid arthritis and Crohn’s disease, similar to infliximab.
Q2: How does biosimilar pricing compare to reference biologics?
A2: Biosimilars typically sell at 20–30% discounts, with prices falling further as market competition intensifies.
Q3: What is the expected market share for this biosimilar by 2025?
A3: Approximately 55–60% of infliximab prescriptions.
Q4: What risks could affect market penetration?
A4: Patent disputes, regulatory delays, physician skepticism, and payer formulary restrictions.
Q5: When will biosimilar prices reach their lowest point?
A5: By 2028, with average prices potentially around $620–$700 per vial.
References
[1] IQVIA. (2022). The Impact of Biosimilars on the U.S. Market.
[2] FDA. (2022). Biosimilar Implementation & Approval Data.
[3] XPharm. (2023). Biosimilar Market Forecasts.
[4] Centers for Medicare & Medicaid Services. (2023). Medicare Prescriber and Pricing Policies.
